Clinical Trial

Neoadjuvant Immunotherapy Plus CRT Versus Neoadjuvant CRT for Locally Advanced Resectable ESCC

Study acronym: iCROSS
Recruiting Phase 2/3
View on ClinicalTrials.gov →
Record status
This record was last updated June 30, 2022 (before its estimated July 2024 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this study was to evaluate the safety, feasibility and outcome of anti-PD-1 antibody (Tislelizumab, BeiGene) combined with neoadjuvant chemoradiotherapy versus neoadjuvant chemoradiotherapy followed by minimally invasive esophagectomy for locally advanced resectable esophageal squamous cell carcinoma (cII-III Stage) patient.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2021-07-13; most recent amendment 2022-06-26.
Status change: Not Yet Recruiting → Recruiting 2022-06-12
Trial Details
NCT Number NCT04973306
Lead Sponsor Shanghai Zhongshan Hospital
Collaborators: Peking University Cancer Hospital & Institute, Shanghai Chest Hospital, First Affiliated Hospital of Wenzhou Medical University, Tianjin Medical University Cancer Institute and Hospital, Ningbo Medical Center Lihuili Hospital, The First People's Hospital of Changzhou, Zhongshan Hospital (Xiamen), Fudan University, Xuhui Central Hospital, Shanghai, Shanghai Minhang Central Hospital, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Zhejiang Cancer Hospital, Sichuan Cancer Hospital and Research Institute, Tongji Hospital, Sun Yat-sen University, Shanghai Fifth People's Hospital
Conditions Esophageal Squamous Cell Carcinoma Stage II, Esophageal Squamous Cell Carcinoma Stage III
Enrollment 176 participants
Start Date 2022-03-02
Primary Completion 2024-07 (estimated)
Study Completion 2027-07 (estimated)
Updated on ClinicalTrials.gov 2022-06-30